Charis C. Papavassilis
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
Journal: Acta dermato-venereologica
Published: February 11, 2022
Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.
Journal: The British journal of dermatology
Published: January 05, 2022
Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: July 20, 2020
Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis.
Journal: The Journal of dermatological treatment
Published: July 10, 2019
Adiponectin levels in a large pooled plaque psoriasis study population.
Journal: The Journal of dermatological treatment
Published: June 11, 2019
Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: August 15, 2018
Reply to Ensina et al.
Journal: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
Published: July 29, 2018
Prevalence and clinical characteristics of chronic spontaneous urticaria in pediatric patients.
Journal: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
Published: April 13, 2018
Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies.
Journal: Drugs & aging
Published: February 07, 2018
No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis.
Journal: The British journal of dermatology
Published: October 10, 2017
Methods for Imputing Missing Efficacy Data in Clinical Trials of Biologic Psoriasis Therapies: Implications for Interpretations of Trial Results.
Journal: Journal of drugs in dermatology : JDD
Published: August 16, 2017
Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study.
Journal: The British journal of dermatology
Published: May 31, 2017
Last Updated: 09/26/2026